Theseactivities are part of the education provided for the California Residency Program Collaborative (CRPC) and available to the general public to improve education, outreach, and treatment for patients with Substance Use Disorder (SUD), including stimulant use disorder, and opioid use disorder with a focus on increasing capacity for effective Medication Assisted Treatment (MAT) implementation. Most of the activities are accredited for CME. For more information, go to
www.familydocs.org/crpc.
The Committee on Continuing Professional Development and CME will be responsible for mitigating any relevant financial relationships disclosed by an individual who may have influence on content, who have served as faculty, or who may produce CME/CPD content for the CAFP. Mitigation may include learner notification, peer review of content before presentation, requirement of EB-CME, changing topics, or even dismissing a potential faculty member.
It is the policy of the CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all continuing education activities. All individuals with potential to influence the content of this program have submitted Disclosure of Interest declarations that have been reviewed according to policy. Learner notification of declarations is below. All individuals with relevant financial relationships with ineligible companies have been contacted by CAFP staff or CCPD members, and issues of conflict have been discussed and mitigated.
Tipu Khan is a consultant and speaker for AbbVie pharmaceutical company, a consultant for Indivior pharmaceutical company, and was formerly a speaker for Alkermes pharmaceutical company, all on the topic of Hepatitis C. These relevant financial relationships have been mitigated.
Allen Wang is a retail investor in two early-stage biopharmaceutical companies, Atossa Genetics and Tonix Therapeutics, unrelated to substance use disorders. These relevant financial relationships have been mitigated.
The AAFP has reviewed CRPC: Education to Improve Services to Patients with OUD/SUD, and deemed it acceptable for AAFP credit. Term of approval is from 08/23/2022 to 08/23/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit approval includes the following session(s):
3a8082e126